RA Capital
Crossover fundActively deployingBoston · Seed–Late Stage · 82 people tracked
Also known as RA CAPITAL MANAGEMENT, LP · RA Capital Nexus · RA Capital Nexus International · RA Capital Planetary Health · RA Capital Planetary Health International
Investment thesis
RA Capital pursues evidence-based, full-lifecycle investing across healthcare, life sciences, and planetary health. It provides multi-stage capital spanning private and public markets, from new company creation and seed-stage incubation through venture rounds, crossover financing, IPO, and later-stage public investing. The firm emphasizes deep landscape research, scientific diligence, and operational company-building support, backed by a team of over 200 people with scientific and operational depth. In healthcare it partners early to shape strategy and define proof points, then provides capital continuity through growth. Its planetary health arm targets near-market, scalable companies advancing resource availability, energy innovation, and industrial productivity. Its Raven platform incubates and co-creates companies to address unmet biomedical needs.
Source: firm website, verified Aug 27, 2026.
Team · 82 people
from the firm's website & curated & public directories
Founder mafia
4 people who came through RA Capital went on to found or lead other companies.
What they invest in
from 186 of 306 portfolio companiesBiotech ×157Healthtech ×97Medical Devices ×73Deep Tech ×22Digital Health ×21AI & Machine Learning ×16Climate Tech ×5Enterprise Software ×5
HQs:United States×138United Kingdom×4Switzerland×2China×2Canada×1Colombia×1
Who they back
founder profiles across 83 portfolio companiesFounding team size:solo founder×382 founders×253 founders×144+ founders×6
Where their founders studiedfrom 22 founders with education data
Massachusetts Institute of Technology ×5Harvard Business School ×3Harvard University ×2MIT Sloan School of Management ×2University of California, Berkeley ×2
Where their founders worked beforefrom 30 founders with career history
MPM BioImpact ×4Johnson & Johnson ×3Genentech ×2Maverick Therapeutics ×2Potenza Therapeutics ×2Stanford University ×2Trieza Therapeutics ×2University of California, Berkeley ×2
Accelerator rootsportfolio companies that came through a program
12 founders hold a PhD · 6 hold an MBA (of 26 with degree data)
Investments · 306 tracked
founders shown can be your intro pathBy year:2026 · 192025 · 162024 · 112023 · 72022 · 42021 · 92020 · 52019 · 32018 · 22017 · 22016 · 32015 · 690 dated
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in
BoardStuart Lawson(Director)
Co-investorsAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin CapitalBain Capital Life Sciences+8 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)Adam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatDerek DiRocco· per SEC Form D · $118M raise · filed Jun 2022
Co-investorsAndera PartnersSamsara BioCapitalSR One Capital ManagementYsios CapitalBoulder VenturesCatalys Pacific
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)in
BoardJean-Francois Formela(Director)inCasper Breum(Director)Vikas Goyal(Director)
Board seatReza Halse· per SEC Form D
Co-investorsHEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)AlphabetAtlas Venture
Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.
BiotechHealthtechLongevitySingapore
Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)in
BoardKen Takanashi(Director)Masaharu Tanaka(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsForesite Capital
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalSofinnova VenturesSofinnova Venture Partners+1 more
HealthtechLaguna Hills, US
Olav Bergheim(Executive Officer, Director)Andrew Wade(Executive Officer)Hugh Neuharth(Executive Officer)
BoardMichael Zhao(Director)James Cox(Director)
BiotechAustin, US
David G. Lowe(Executive Officer, Director)George Georgiou(Director)Charles N. York(Executive Officer)in
BoardHenry Skinner(Director)Armen Shanafelt(Director)
BiotechHealthtechMedical DevicesLexington, US
Garo Armen(Executive Officer, Director)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)Karen Valentine(Executive Officer)
BoardBrian Corvese(Director)
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalInvus+1 more
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)in
BoardHelen S. Kim(Director)Oleg Nodelman(Director)inAndrew Levin(Director)
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundTCG CrossoverVida Ventures+2 more
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)
Co-investorsAdjuvant CapitalBioRock VenturesFlucas VenturesMountain Group CapitalHatteras Venture Partners
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Hendersonin
Co-investorsAccess Biotechnology
BiotechWestlake Village, US
Alexander Asam(Director)Ricky Sun(Director)Todd Franklin Watanabe(Executive Officer, Director)
BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)
Co-investorsBain Capital Life SciencesFrazier Life Sciences
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)in
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)inTim Shannon(Director)inKush Parmar(Director)
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestSolasta Ventures+1 more
Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).
BiotechHealthtechBoston, US
Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)
BoardBruno Lucidi(Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)
Co-investorsBain Capital Life Sciences
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRed Tree Venture+1 more
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalOrbiMed+4 more
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.
BiotechHealthtechMedical DevicesConnecticut, US
Vlad Coric, M.D.(Chairman & Chief Executive Officer)
Co-investorsOberland CapitalSixth Street
Co-investorsVersant Ventures
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life SciencesNovo Holdings+1 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)inCarolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)
Co-investorsARCH Venture PartnersNextech Invest
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesNextech Invest
Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Josef Parvizi(Director)inXingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)
Co-investorsLongitude CapitalRed Tree VentureShangBay Capital LLC
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalTCG CrossoverACORN BIOVENTURES+2 more
Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma.
BiotechHealthtechSan Diego, US
Co-investorsCo-Win Ventures
Co-investorsSR One Capital Management
A pharmaceutical company whose executive team emphasizes innovation and patient care.
BiotechDigital HealthMental Health
Co-investorsForesite Capital
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Arix BioscienceOrbiMed
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture Partners+1 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more
PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
James McArthur(Executive Officer, Director)in
BoardRamin Farzaneh-Far(Director)Joshua Resnick(Director)Christopher Ashton(Director)Heidi Henson(Director)
Co-investorsOxford Science Enterprises
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more
HealthtechBoston, US
BoardDavid Steinberg(Executive Officer, Director)Christoph Westphal(Director)Geeta Vemuri(Director)Jak Knowles(Director)John Flavin(Director)Lucio Iannone(Director)
Co-investorsLongwood FundAgent Capital
BiotechSan Jose, US
Talat Imran(Executive Officer, Director)Svai Sanford(Executive Officer)Mir Hashim(Executive Officer)
BoardAbraham Bassan(Director)Vasudev Bailey, M.D.(Director)Mir Imran(Director)
Co-investorsInCube Ventures
RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.
HealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)in
BoardJavier Perez-Sala(Director)Jan Bonel(Director)
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalVisionary Ventures+1 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Co-investorsAndreessen HorowitzOrbiMedAvoro Capital AdvisorsMenlo VenturesAvoro Ventures
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)
Co-investorsFlagship PioneeringSofinnova Ventures
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Stephen DiPalma(Executive Officer)Alexander (Bo) Cumbo(Executive Officer, Director)Carl Morris(Executive Officer)inMartin Freed(Director)Paul Herizch(Executive Officer)Robert Huffines(Director)
Co-investorsBain Capital Life SciencesForesite Capital
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Co-investorsNew Enterprise Associates (NEA)Samsara BioCapitalVensana Capital
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude Capital
Co-investors5AM VenturesOUP (Osage University Partners)
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRiverVest Venture Partners+4 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsINCE CapitalBiotechnology Value FundJanus Henderson InvestorsREDMILESalvia
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)inScott Boyken(Co-founder & Chief Technology Officer)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Board seatJake Simson· per SEC Form D
Co-investorsArtis VenturesAbstract VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, LlcModi VenturesPlayground Global+1 more
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndreessen HorowitzMagnetic VenturesOMX VenturesAxial VCGV (Google Ventures)LoLa Capital Partners+1 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)Samsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+8 more
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonBpifranceAndera PartnersAngelini VenturesKurma PartnersPontifax Venture Capital+1 more
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.DCVC (Data Collective)
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)Mark Pruzanski(Chief Executive Officer)Luigi Manenti(Chief Medical Officer)Jon Freve(Chief Financial Officer)Bryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+5 more
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)in
Co-investorsLux CapitalThe Column GroupNextech Invest
Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.
Deep TechDefense TechEnergyRichland, US
Robin Langtry(Co-Founder, CEO)inBrian Riordan(Co-Founder, COO)in
Co-investorsCongruent VenturesFounders FundLowercarbon CapitalToyota VenturesAzolla VenturesJuniper+2 more
Bia is a technology-driven electricity retailer in Colombia that lets businesses switch their energy provider and replace traditional meters with its proprietary BiaMonitor smart meter.
CleantechEnergyIoTBogota, CO
Sebastian Ruales(Founder)Guillermo Plaza Roche(Director)Leonardo Velazquez Florez(Director)Juan Sebastian Ruales Duque(Director)Jaime E. Zunzunegui(Director)
BoardNicolas Berman(Director)in
Co-investorsBBVA SPARKIDB LabKaszek VenturesMarathon VenturesNazcaNorte Ventures+2 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsJohnson & Johnson Innovation – JJDCVersant VenturesVenrockFidelity InvestmentsInvusQatar Investment Authority
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)Kenneth Horne(Executive Officer, Director)inDylan Morris(Director)Cristina Ghenoiu(Director)
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersAN Venture PartnersRDiscovery
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
William Wei Cao
Co-investorsLAVLilly Asia VenturesOrbiMedExome Asset ManagementJanus Henderson InvestorsPivotal Life Sciences+2 more
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)
Co-investorsDroia VenturesEisai Innovation, Inc.Novartis Venture Fund
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
BoardLori Hu(Director)
Co-investorsLeaps by BayerVertex Ventures HC
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureEQT Life SciencesSixty Degree CapitalVivo CapitalGimv+1 more
MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.
HealthtechMedical DevicesRoboticsJacksonville, US
Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)Theresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)
Co-investorsAndera PartnersBioStar CapitalDeerfield Management CompanyFidelity InvestmentsCorewell Health VenturesFountain Healthcare Partners
PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).
BiotechHealthtech
Co-investorsAN Venture PartnersUTEC
Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.
AgTechBiotechClimate TechSt. Louis, US
Barry Goldman(Co-founder)Elizabeth Gallegos(Chief Executive Officer)Jerry Steiner(Executive Chair)Charlie Walch(Executive Officer, Director)Glendon Schuster(Director)
Co-investorsFirst In VenturesIllumina VenturesRadicle GrowthBetter VenturesFall Line CapitalGrantham Foundation+4 more
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureOrbiMed
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsLongitude CapitalVisionary Ventures
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesPfizer Venture Investments
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.
BiotechHealthtechMedical DevicesSan Mateo, US
Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)
BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)inTim Shannon(Director)in
Co-investorsCanaan PartnersCenova CapitalMission Biocapital
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
erick gamelinin
Board seatDerek DiRocco· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Pureos Bioventures
Structure-based small-molecule drug design targeting protein aggregation diseases.
BiotechThousand Oaks, US
James Treanor(Also a former CEO)Gary Wilcox(Director)John Frank(Director)Madhavan Balachandran(Executive Officer, Director)
Board seatReza Halse· per SEC Form D · $6M raise · filed Dec 2020
Co-investorsMRL Ventures Fund
Boston, US
Board seatAndrew Levin· per SEC Form D
Co-investorsOUP (Osage University Partners)
HealthtechCambridge, US
Clarence Friedman(Executive Officer, Director)
Board seatPeter Kolchinsky· per SEC Form D · $3.1M raise · filed Sep 2017
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsNextech InvestOrbiMedSR One Capital Management
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatLaura Stoppel· per SEC Form D
Co-investors5AM VenturesEcoR1 CapitalvenBio PartnersvenBio Global Strategic
BiotechTucson, US
Louis Breton(Executive Officer, Director)David Baltimore, Ph.D.(Director)Bhavin Raval(Executive Officer)
BoardJon Faiz Kayyem, Ph.D.(Director)Harry A. George(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsCycad Group LLCAlexandria
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)Neil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)Alexander Brown(Executive Officer)
BoardTal Zaks(Director)
Board seatJake Simson· per SEC Form D
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)
Board seatDerek DiRocco· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersThe Column Group
Menlo Park, US
Kevin Judice(Executive Officer, Promoter)Michael Rabson(Executive Officer, Promoter)
Board seatJake Simson· per SEC Form D · $81.5M raise · filed Jan 2021
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(Executive Officer, Director)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+2 more
Philadelphia, US
Gabriel Otte(Executive Officer, Director)
BoardCharles Roberts(Director)
Board seatPeter Kolchinsky· per SEC Form D · $300M raise · filed Dec 2021
Co-investorsAndreessen HorowitzPolaris Partners
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsLumira VenturesMountain Group CapitalSolasta VenturesHatteras Venture Partners
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsSanofi VenturesQiming Healthcare
Wakefield, US
BoardJoshua S. Phillips(Executive Officer, Director)inDarshana Zaveri(Director)
Board seatPeter Kolchinsky· per SEC Form D · $3M raise · filed Aug 2017
Co-investorsCatalyst Health Ventures
BiotechBoston, US
Naveen Manu Daryani(Executive Officer)William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Director, Promoter)
BoardGianna Hoffman-Luca(Director)
Board seatAndrew Levin· per SEC Form D · $45M raise · filed Feb 2026
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BoardMegan Krench(Director)Dmitrij Hristodorov(Director)in
Board seatZach Scheiner· per SEC Form D
Co-investorsSanofi VenturesAvego BioScience CapitalForbionSamsara BioCapital
BiotechWaltham, US
Qimin Quan(Executive Officer)Philippe Mourere(Executive Officer, Director)Joseph Wilkinson(Executive Officer)Scott Sherman(Executive Officer, Director)Elouise P. Manhertz(Executive Officer)
BoardJohn Boyce(Director)
Board seatAnurag Kondapalli· per SEC Form D
Co-investorsTime BioVenturesInsight PartnersPura Vida Investments
BiotechRio Rancho, US
Alexander Koglin(Executive Officer, Director, Promoter)James Coffin(Executive Officer, Director)Michael Humbert(Executive Officer, Director, Promoter)
BoardDavid Seldin(Director)Edward Liddy(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsAnzu PartnersBlueStone Venture Partners
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Board seatDerek DiRocco· per SEC Form D · $57M raise · filed Jan 2025
Co-investorsMedicxiLongitude Capital
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)Elizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)
Board seatJake Simson· per SEC Form D
Co-investorsCatalio Capital Management, LPSamsara BioCapitalVertex Ventures HCThird Rock Ventures
BiotechArlington, US
Daniel S. Grau(Executive Officer, Director)
BoardScott L. Rakestraw(Director)
Board seatPeter Kolchinsky· per SEC Form D · $44M raise · filed Nov 2018
BiotechBoston, US
David Feltquate(Executive Officer)Maiken Keson-Brookes(Executive Officer)CAROLINE LOEW(Executive Officer, Director, Promoter)
BoardJULIE GRANT(Director)in
Board seatEmily MinkowAndrew Levin· per SEC Form D
Co-investorsCanaan PartnersForbion
BiotechWaltham, US
CATHERINE RIESEN(Executive Officer)CONY D'CRUZ(Executive Officer, Director, Promoter)CRAIG RANDALL(Executive Officer)
BoardDIAMANTIS XYLAS(Director)DYLAN MORRIS(Director)
Board seatAndrew Levin· per SEC Form D
Co-investorsGaingelsInsight PartnersNVIDIA
BiotechCambridge, US
Livio Valenti(Executive Officer)Kathryn Kosuda(Executive Officer, Director)Michael Schrader(Executive Officer, Director)Matthew Dirckx(Executive Officer)Lynda Tussey(Executive Officer)John Spiridigliozzi(Executive Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsGlobal Health Investment CorporationMission Biocapital
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Board seatDerek DiRocco· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundMPM BioImpactTaiho Ventures, LLC
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture Capital+2 more
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsBain Capital Life SciencesSofinnova Ventures
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)Sofinnova VenturesCowen Healthcare InvestmentsFidelity Investments+1 more
Co-investorsSV Health Investors
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos Capital
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestInkef
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsFrazier Life SciencesOrbiMedFrazier
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.
BiotechDeep TechHealthtechEmeryville, US
Dan Lin-Arlow(Founder)inSebastian Palluk(Founder)inDaniel Lin-Arlow(Executive Officer, Director)inDaniel Hillel Lin-Arlow(Executive Officer, Director)Jason T. Gammack(Executive Officer, Director)in
BoardYanniv Dorone(Director)
Co-investorsCarbon SiliconDauntless VenturesFifty YearsMetaplanetY CombinatorFall Line Capital+2 more
Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications.
Climate TechDeep TechIoTRoboticsCambridge, US
Ravi Pappu(CEO / Board Member)
BoardSanjeev Krishnan(Director)Jonathan Rosen(Director)David Douglas(Director)Kyle Teamey(Director)Mark Abbott(Director)
Co-investorsBay Bridge Ventures ClimateCoalitionS2G InvestmentsTFX Capital
Co-investorsM VenturesNovartis Venture Fund
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersM VenturesNovartis Venture FundPfizer Venture InvestmentsSofinnova PartnersSV Health Investors
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsForesite CapitalSofinnova Ventures
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalY CombinatorJanus Henderson Investors+2 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyvenBio PartnersDeerfield Management CompanyOrbiMedVenrock
Avalanche provides software development tools that startups can integrate to build and operate referral programs within their products.
Enterprise SoftwareMarketing TechSan Francisco, US
Elezhan (Ijan) Zhakiya(Founder)in
Co-investorsLowercarbon CapitalY Combinator8090 IndustriesCongruent VenturesFounders FundToyota Ventures
The Avalanche Foundation is a non-profit organization that supports innovation and growth in the Avalanche ecosystem through grants, programs, and strategic support for developers, entrepreneurs, and communities building on the Avalanche blockchain platform.
Crypto & Web3Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintech
Emin Gun Sirer(Founder)in
Co-investorsa16z cryptoAegis VentuesAndreessen HorowitzAndromeda CapitalBaseTwoBig Brain Holdings+25 more
Ava Labs is a company building blockchain infrastructure and tools for creating and using finance applications.
Crypto & Web3Data & InfrastructureDeep TechFintechNew York City, US
Emin Gün Sirer(Founder & CEO)in
Co-investorsAnimoca BrandsAbstract VenturesCeras VenturesContinue CapitalLvna Capital8090 Industries+5 more
New gene therapy treatments for people with serious, rare diseases.
BiotechBannockburn, US
Brian Kaspar(Executive Officer, Director)James L'Italien(Executive Officer)Andrew F. Knudten(Executive Officer)Sukumar Nagendran(Executive Officer)Thomas Dee(Executive Officer)Sean Nolan(Executive Officer, Director)
Co-investorsForesite CapitalPBM CapitalSofinnova Ventures
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCMedical Excellence CapitalSanofi VenturesOpenSky Ventures
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in
Co-investorsThird Rock VenturesSozo VenturesYosemite
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
BiotechHouston, US
David M. Spencer(Executive Officer)Ken Moseley(Executive Officer)Thomas J. Farrell(Executive Officer, Director)Annemarie Moseley(Executive Officer)Joseph Senesac(Executive Officer)
BoardKevin M. Slawin(Executive Officer, Director)
Co-investorsForesite CapitalRapha Capital Management, LLC
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersSanofi Ventures
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRiverVest Venture PartnersHBM Healthcare InvestmentsNovo HoldingsT. Rowe PriceWellington Management
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalForesite CapitalNextech Invest
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsPfizer Venture InvestmentsSofinnova VenturesVida Ventures
Co-investorsFrazier Life Sciences
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
BiotechHealthtechMedical Devices
Co-investorsLeaps by BayerPureTech Health
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesVivo CapitalCanaan Partners+1 more
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)
BoardROB HOPFNER(Director)
Co-investorsCanaan PartnersSofinnova VenturesBay City CapitalLongitude CapitalOrbiMed
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical Devices
Clarke Atwell(Co-Founder and Chief Operating Officer)
Co-investorsSofinnova VenturesNovo Holdings
Co-investorsEcoR1 Capital
Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).
FintechSaaS
Aldric Emié(CEO)
Co-investorsKima VenturesAlly Bridge GroupREDMILE
Commons Clinic is an orthopedic care provider offering treatment for spine, joint, and sports medicine conditions, along with preventive health services such as full-body MRI and biomarker labs.
Digital HealthHealthtechWellness & FitnessAustin, US
Brad Hively(Director)Nick Aubin(Founder)inPaulo Marques Da Costa(Executive Officer, Director)Prithviraj Singha Roy(Director)
BoardJohn Loser(Director)inDavid Berry(Director)
Co-investorsCourtside VenturesFloating PointNorth South VenturesSteelSky VenturesTime BioVenturesAverin Capital
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)
PartnerLaura Stoppel· quoted
Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture Capital+14 more
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Co-investorsTechstarsAndreessen HorowitzOrbiMed
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Biotech
Co-investors5AM VenturesOrbiMed
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)Gregory S. Curhan(CFO)Guy De La Rosa(CMO)
Co-investorsAdjuvant CapitalOrbiMedSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.
BiotechData & InfrastructureHealthtechSaaS
Chris
Co-investorsTinySeedAlgerREDMILERTW Investments L.P.Sofinnova Ventures
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesPsyMed VenturesVertical Venture Partners+3 more
Co-investorsFrazier Life Sciences
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function.
BiotechDigital HealthMedical DevicesResearch Triangle Park, US
Edward C Burgard(Executive Officer, Director, Promoter)Karl Thor(Executive Officer, Director, Promoter)Benny Ward(Executive Officer, Director, Promoter)
BoardFred Eshelman(Director)inDaniel J Ricca(Director, Promoter)Ebrahim Versi(Director, Promoter)
Co-investorsEshelman Ventures, LLC
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)Arthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyExSight VenturesJanus Henderson Investors
BiotechSan Francisco, US
NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)
Co-investorsForesite Capital
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
Co-investorsOrbiMedWestlake Village BioPartnersNVIDIA
Co-investorsCatalio Capital Management, LPGeneral Catalyst
Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.
BiotechDeep TechHardwareMedical Devices
Co-investorsDraper AssociatesForesite CapitalFusionTSVCVenrock
European biopharmaceutical company advancing a nectin-4 antibody-drug conjugate for solid tumour oncology.
Co-investorsHadean VenturesPontifax Venture Capital
Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life.
AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US
Rosalind Picard(Founder and Director of the Affective Computing Group at the MIT Media Lab and Faculty Chair, MIT Mind+Hand+Heart Wellbeing Initiative)Matteo Lai(Executive Officer, Director)inSimone Tognetti(Director)Len Picard(Executive Officer, Director)Mario Scuderi(Director)
Co-investorsBlack Opal VenturesCDP Venture CapitalSanofi Ventures
Co-investorsM VenturesPfizer Venture Investments
Co-investorsDecheng Capital
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)inOliver Stauch(Executive Officer)inConrad Wang(Director)
Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio PartnersvenBio Global Strategic
Familiar Machines develops emotionally intelligent physical AI, including the underlying models and hardware, for consumer home use.
AI & Machine LearningConsumerRoboticsWoburn, US
Colin Angle(CEO & Co-founder)Chris Jones(CRDO & Co-founder)inIra Renfrew(C2PO & Co-founder)
Co-investorsData Point Capital
Farcast develops advanced satellite communication user terminals with flat panel phased array antennas that electronically track satellite movement for reduced size, weight, power, and cost.
Advanced ManufacturingHardwareSpace TechSan Francisco, US
Siamak Ebadi(Founder)in
BoardDavid Byrd(Director)inGuido Jouret(Director)
Co-investorsBlueYard CapitalFifty YearsGarage CapitalMaC Venture CapitalY CombinatorLockheed Martin Ventures+1 more
Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure.
Advanced ManufacturingBiotechHealthtechMedical DevicesGrove City, US
Timothy J. Miller(Executive Officer, Director)in
BoardChris Garabedian(Director)Molly McCartin(Director)in
Co-investorsAisling CapitalDrive Capital
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactDCVC BioDeerfield Management Company
Gameto develops cell therapy and reproductive technologies to treat infertility and improve women's health outcomes.
BiotechFemTechHealthtechMedical DevicesAustin, US
Dina Turner(Co-founder & Chief Executive Officer)inMartin Varsavsky(Co-founder & Chairman)inDina Radenkovic(Executive Officer, Director)
BoardDusan Perovic(Director)inDylan Morris(Director)Maryanna Saenko(Director)in
Co-investorsBold Capital PartnersFuture VenturesIngeborg InvestmentsJazzya InvestmentsKorify CapitalLux Capital+11 more
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.
BiotechHealthtechMedical Devices
Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)
Co-investorsNovartis Venture FundOrbiMedJDRF T1D Fund
GIVAX is a biotechnology company focused on vaccine development.
BiotechHealthtech
John Patton(Scientific Co-Founder)Mario Barro(President & CEO)in
South San Francisco, US
John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in
BoardKevin Starr(Director)inCharles Homcy, M.D.(Director)
Co-investorsThird Rock Ventures
Halda provides AI agents for higher-education enrollment, including a campaign agent for personalized email outreach, a website conversion agent, and an always-on recruiter agent that responds to students via text, email, voice, and WhatsApp.
AI & Machine LearningEdTechSaaSProvo, US
Lance Hydrick(Executive Officer, Director)Dallin Palmer(Director)
BoardSid Krommenhoek(Director)in
Co-investorsAlbum VCFrazier Life SciencesKickstartAlbum Ventures
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesTaiho Ventures, LLCVida Ventures
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapital
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases.
BiotechMedical Devices
Co-investorsAndreessen HorowitzNextech Invest
ILiAD Biotechnologies is a clinical-stage biotechnology company developing vaccines and treatments for disease caused by Bordetella pertussis, with a lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials.
BiotechHealthtechWeston, US
Keith Rubin(Executive Officer, Director)William Steinkrauss(Executive Officer)KEN SOLOVAY(Executive Officer)
BoardEric Edidin(Director)Avi Naider(Director)Mario Barro(Director)
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)Albert M. Kim(Chief Medical Officer)
Co-investorsAN Venture PartnersSanofi VenturesSV Health InvestorsCatalio Capital Management
BiotechBoston, US
Pavan Cheruvu(Director)Alvin Shih(Executive Officer, Director)Komal Joshi(Executive Officer)Pieter Boelhouwer(Director)David-Alexandre C. Gros(Executive Officer, Director)
BoardCharles Dunn(Director)
Co-investorsCatalio Capital ManagementSV Health Investors
Co-investorsBain Capital Life Sciences
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)inBrendan Eckelman(Director)inDoug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
Co-investorsLAVLilly Asia VenturesOxford Finance LLC
Browse all 306 investments with full details →
▶106 more tracked companies
InozymeInterius BioIO BiotechIvantisJanuxJnana TherapeuticsJunoKalvistaKinnateKinnate BiopharmaKolomaLegend BioLenzLifeMineLumenaLyraMagenta MedicalMarianaMariana OncologyMBXMementoMerusMetagenomiMetseraMineralysMMI MicroModernaNapiGenNavaNavigator MedicinesNexCureNextopNiKang TherapeuticsNimbus TherapeuticsNivalisNorthLinks BioNucleixObsidian TherapeuticsOlemaOllinOptivoltOrchardPAhR TherapeuticsPandionPelotonPhathomPinnacle MedicinesPlantiblePluton BioPMV PharmaPoint BiopharmaPoplar TherapeuticsPrevailProfound BioProtagonistRa PharmaceuticalsRadenceReframe SystemsReframe SystemsRivus PharmaSatsumaSeagenSecretome TherapeuticsSerapha BioShockwaveSidera BioSierra OncologySilverback TherapeuticsSlate MedicinesSomatusSortera TechnologiesSparrow PharmaStar TherapeuticsStokeStylus MedicineSuperluminalSynapticureSynolo TherapeuticsSynthegoSynthekineSynthorxT-KnifeTaris BiomedicalTassoTenayaTerremotobioterrestrialThriveworksTopl (Now Plasma)Torl BioTrace NeuroscienceTriana BioTscanTScan TherapeuticsTypewriter TherapeuticsTyraVentusVentus TherapeuticsVerdiva BioVerve TherapeuticsViacyteVitriVaxVividionVoro MetalsWhiteSwellWindward Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 47
IPOs and acquisitions across the tracked portfolioFreenomeNASDAQ: FRNMMineralys TherapeuticsNASDAQ: MLYSSpero TherapeuticsNASDAQ: SPROWave Life SciencesNASDAQ: WVEAclaris TherapeuticsNASDAQ: ACRSAdagio MedicalNASDAQ: ADGMAeglea BiotherapeuticsNASDAQ: SYREAgenusNASDAQ: AGENAktis OncologyNASDAQ: AKTSAN2 TherapeuticsNASDAQ: ANTXApogee TherapeuticsNASDAQ: APGEArcutis BiotherapeuticsNASDAQ: ARQTArvinas Holding Co. LLCNASDAQ: ARVNAtea PharmaceuticalsNASDAQ: AVIRBicara TherapeuticsNASDAQ: BCAXBioAge LabsNASDAQ: BIOABiohavenNYSE: BHVNBlack Diamond TherapeuticsNASDAQ: BDTXBolt BiotherapeuticsNASDAQ: BOLTBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCCentury TherapeuticsNASDAQ: IPSCCeribellNASDAQ: CBLLCG OncologyNASDAQ: CGONClimbbioNASDAQ: CLYMConnect BiopharmaNASDAQ: CNTBDesign TherapeuticsNASDAQ: DSGNGH ResearchNASDAQ: GHRSImaraNASDAQ: ELVNNateraNASDAQ: NTRAnKartaNASDAQ: NKTXParabilis MedicinesNASDAQ: PBLSPepGenNASDAQ: PEPGPrecision BioSciencesNASDAQ: DTILPyxis OncologyNASDAQ: PYXSRani Therapeutics HoldingsNASDAQ: RANIRxsightNASDAQ: RXSTScribe TherapeuticsNASDAQ: SCTXSeres TherapeuticsNASDAQ: MCRBSionna TherapeuticsNASDAQ: SIONSolid BiosciencesNASDAQ: SLDBSpyglass PharmaNASDAQ: SGPVaxcyteNASDAQ: PCVXVor BiopharmaNASDAQ: VORXilio TherapeuticsNASDAQ: XLODTx Pharmaacq. by NovartisHilleVaxacq. by XOMA Royalty
Portfolio news
latest coverage across their companiesInhibrx · ng.investing.com · Aug 21, 2026
Cidara Therapeutics · tradingkey.com · Aug 20, 2026
Pyxis Oncology · scanx.trade · Aug 20, 2026
Arcutis Biotherapeutics · streetinsider.com · Aug 19, 2026
Abcuro · clinicaltrialsarena.com · Aug 19, 2026
AN2 Therapeutics · ng.investing.com · Aug 19, 2026
CG Oncology · investing.com · Aug 19, 2026
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Dec 2018
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
450 insider ownership filings (Forms 3/4/5)
at Septerna, Inc. (SEPN), Inhibikase Therapeutics, Inc. (IKT), Artiva Biotherapeutics, Inc. (ARTV), Freenome, Inc. (FRNM), Parabilis Medicines, Inc. (PBLS), Vor Biopharma Inc. (VOR), Climb Bio, Inc. (CLYM), ARS Pharmaceuticals, Inc. (SPRY)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has RA Capital made?
- RA Capital has 265 tracked investments, 10 of which have exited via acquisition or IPO, including 22 dated in the last 24 months.
- What stage does RA Capital invest at?
- RA Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does RA Capital focus on?
- RA Capital focuses on Biotech, Climate Tech, Digital Health, Healthtech, Medical Devices.
- Where is RA Capital located?
- RA Capital is headquartered in Boston, US.
- Does RA Capital lead rounds?
- RA Capital has led 6 of the 24 rounds where its role is on record.
- Who does RA Capital co-invest with?
- RA Capital most often shares deals with Foresite Capital, OrbiMed, Bain Capital Life Sciences, among 237 tracked co-investors.
- What size deals does RA Capital back?
- Across 13 deals with disclosed amounts, RA Capital has joined rounds of $20M – $318M (median $103M).
Media · Podcasts & interviews
featuring the teamThe Investor's Paradox with Peter Kolchinsky, RA Capital
Incubate Coalition · Peter Kolchinsky
Images
Co-investors · 71
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
▶59 more co-investors
F-Prime CapitalAtlas Venture5AM VenturesvenBio PartnersSV Health InvestorsVersant VenturesAndera PartnersMRL Ventures FundARCH Venture PartnersThird Rock VenturesAisling CapitalSR One Capital ManagementForbionPivotal Life SciencesNovartis Venture FundRTW Investments L.P.General CatalystInsight PartnersVenrockArtis VenturesMPM BioImpactThe Column GroupRed Tree VentureUS Venture PartnersEQT Life SciencesHatteras Venture PartnersNew Leaf Venture PartnersVertex Ventures HCHumboldtPolaris PartnersTwo Sigma VenturesPlayground GlobalJohnson & Johnson Innovation – JJDCYsios CapitalRoche Venture FundQiming Venture PartnersAnzu PartnersMedical Excellence CapitalHealthCapPsyMed VenturesOverwater Ventures LlcUnknown VenturesKleiner PerkinsCoatue ManagementAtomicoSignalFire23andMeXtripe AngelsBaruch Future VenturesMithril Capital ManagementXSeed CapitalAccess IndustriesOmega FundsTencent HoldingsCofounders CapitalAbbVieDe Novo VenturesQiming Venture Partners USANegev Capital
Firms observed investing alongside RA Capital, from public investor directories. Shared companies are the overlap with RA Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
JSTAR Capital Investments is a healthcare-focused investment firm backing medical technology companies, providing capital and expert guidance to advance patient care and address global healthcare challenges.